Brokers Watch List: Sirius XM Holdings Inc. (NASDAQ:SIRI), Juno Therapeutics Inc. (NASDAQ:JUNO)

Sirius XM Holdings Inc. (NASDAQ:SIRI)

The company announced its last quarter financial performance results on 10/27/2016. Sirius XM Holdings Inc. (NASDAQ:SIRI) belongs to NA sector that declined -0.43% in value when last trading session closed at $4.59. The company has a market capitalization of $22.24 Billion. The company’s stock has a Return on Assets (ROA) of 8.8 percent, a Return on Equity (ROE) of -141.7 percent and Return on Investment (ROI) of 15.1 percent. The company reached its 52-Week high of $4.65 on Nov 23, 2016 and 52-Week low of $3.29 on Feb 8, 2016.

Earnings per share (ttm) for Sirius XM Holdings Inc. (NASDAQ:SIRI) according to Finviz Data is $0.14.

The growth estimate for Sirius XM Holdings Inc. (NASDAQ:SIRI) for the current quarter is 33.3 percent. The projected growth estimate for the next quarter is 33.3 percent. The company’s stock has grown by 12.98 percent in the past 5 years. For the next 5 years, the company is expected to grow by 15 percent.

This company was Initiated by Telsey Advisory Group on 12-Jul-16  to Market Perform.

The 15 analysts offering 12-month price forecasts for Sirius XM Holdings Inc have a median target of 4.85, with a high estimate of 5.55 and a low estimate of 4.50. The median estimate represents a +5.66% increase from the last price of 4.59.

Financial History for Sirius XM Holdings Inc. (NASDAQ:SIRI):

Following Earnings result, share price were UP 13 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 0% percent of times. It has met expectations  9  times and missed earnings  3  times.

The consensus recommendation for Sirius XM Holdings Inc. (NASDAQ:SIRI) is 1.77. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.77. In comparison, the consensus recommendation 60 days ago was at 1.77, and 90 days ago was at 1.77 respectively.

Future Expectations for Sirius XM Holdings Inc. (NASDAQ:SIRI):

When the current quarter ends, Wall Street expects Sirius XM Holdings Inc. to have earnings per share of $0.04.

Revenue is expected to range from 1.28 Billion to 1.31 Billion with an average of 1.29 Billion.

Company Profile:

Sirius XM Holdings Inc. is a radio broadcasting company. It creates and broadcasts commercial-free music; premier sports and live events; news and comedy; exclusive talk and entertainment; and the most comprehensive lineup of Latin commercial-free music, sports, and talk programming in radio. SiriusXM content is available via satellite and through the SiriusXM Internet Radio app for smartphones and other connected devices, as well as online at siriusxm.com. Sirius XM Holdings Inc., formerly known as Sirius XM Radio Inc., is headquartered in New York.

Juno Therapeutics Inc. (NASDAQ:JUNO):

Juno Therapeutics Inc. (NASDAQ:JUNO) belongs to NA sector closed its last session with a loss of -24.5 percent and closed its previous trading session at $22.56. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-2.81. The company has the Market capitalization of $2.44 Billion. The company’s stock has a Return on Assets (ROA) of -19 percent, a Return on Equity (ROE) of -24 percent and Return on Investment (ROI) of -20.3 percent. The company reached its 52-Week high of $57.82 on Dec 1, 2015 and 52-Week low of $19.41 on Nov 23, 2016.

This company was Downgrade by FBR & Co. on 23-Nov-16 to Mkt Perform.

The 12 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 45.00, with a high estimate of 61.00 and a low estimate of 23.00. The median estimate represents a +99.47% increase from the last price of 22.56.

Financial History for Juno Therapeutics Inc. (NASDAQ:JUNO):

Following Earnings result, share price were UP 4 times out of last 7 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Juno Therapeutics Inc. (NASDAQ:JUNO) is 1.9. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.78. In comparison, the consensus recommendation 60 days ago was at 1.63, and 90 days ago was at 1.63 respectively.

Future Expectations for Juno Therapeutics Inc. (NASDAQ:JUNO):

When the current quarter ends, Wall Street expects Juno Therapeutics Inc. to have earnings per share of $-0.62.

Revenue is expected to range from 7.5 Million to 20.3 Million with an average of 13.96 Million.

Company Profile:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

You may missed